The SCALE Trial: Liraglutide for Weight Loss in Obese Patients
In a randomized, controlled trial, researchers compared liraglutide — a GLP-1 agonist approved for the treatment of type 2 diabetes — with placebo to assess its potential for inducing weight loss in overweight or obese adults without diabetes.
Results indicated that patients in the liraglutide group experienced greater weight loss than those in the placebo group.
Gastrointestinal problems were the most commonly reported adverse events.
Watch the full video for a more detailed breakdown of data from the SCALE trial.